A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

Exclusion Criteria

• - History of clinically significant cardiovascular, respiratory, hepatic, renal,
• gastrointestinal, endocrinological, hematological, neurological or other disorders.
• - History of meningococcal infection.
• - History of additional risk factors for Torsades de Pointes (eg, heart failure, hypokalemia, family history of Long QT syndrome).
• - History of clinically significant hypersensitivity or idiosyncratic reaction to the study intervention or related compounds.
• - History of unexplained, recurrent infection, or infection requiring treatment with systemic antibiotics within 14 days prior to Period 1 Day 1.
• - History of significant multiple and/or severe allergies (hay fever is allowed unless it is active), including significant hypersensitivity reactions to commonly used antibacterial agents, including beta-lactams, penicillin, amoxicillin, aminopenicillin, fluoroquinolones (specifically including ciprofloxacin), cephalosporins, and carbapenems, which in the
• opinion of the Investigator would make it difficult to provide empiric antibiotic therapy or treat an active infection.
• - Diseases or conditions or previous procedures known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
• - History of malignancy within 5 years prior to screening, with the exception of nonmelanoma skin cancer or carcinoma in situ of the cervix that has been treated with no evidence of recurrence.
• - Known hepatic or biliary abnormalities (including participants with Gilberts syndrome).
• - Participants with a history of cholecystectomy or gall stones.